<DOC>
	<DOCNO>NCT00208273</DOCNO>
	<brief_summary>This trial compare grade 2 great late skin toxicity concomitant letrozole-radiotherapy radiotherapy follow letrozole adjuvant therapy postmenopausal woman receptor ( estrogen receptor [ ER ] and/or progesterone receptor [ PgR ] ) positive tumor . Each drug prescribe 5 year .</brief_summary>
	<brief_title>Concomitant Sequential Radiohormonotherapy Adjuvant Breast Cancer</brief_title>
	<detailed_description>This trial open-label randomized multicenter phase II study . A ratio 1 1 used randomization process two arm : - Arm A : Letrozole 2.5 mg daily 5 year start three week first day adjuvant radiotherapy . - Arm B : Letrozole 2.5 mg daily 5 year start three week last day adjuvant radiotherapy . All patient follow every 3 month toxicity , disease status survival death .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Compliant postmenopausal woman Conservative breast cancer surgery Extension evaluation disease proven negative Patients tumor negative margin Patients classify T1 , T2 , T3 ; Sentinel node negative , N0 , N1 N2 ; M0 . Receptor positive tumor ( ER and/or PgR = 10 fmol/mg cytosol protein ; = 10 % tumor cell positive immunocytochemical evaluation ) . Adequate marrow function ( polynuclear neutrophil &gt; = 1200.10^9/l , platelet &gt; = 100.10^9/l , hemoglobin &gt; = 10 g/dl ) . Hepatic function ( bilirubin &gt; = 30 Âµmol/l , ALT ( SGPT ) AST ( SGOT ) &gt; = 1.5 x upper limit institution ) cholesterol level &lt; 2 x upper limit institution . Must geographically accessible followup . Written date informed consent Patients distant metastasis . Bilateral breast cancer ( concomitant prior ) except situ lesion , either ductal lobular , contralateral breast . Patients stag T4 N3 treat conservative surgery ( radical mastectomy ) . Patients neoadjuvant chemotherapy hormonal therapy . Patients previous concomitant ( breast cancer ) malignancy within past 5 year EXCEPT adequately treat basal squamous cell carcinoma skin situ carcinoma cervix . Patients previous malignancy must disease free least five year . Patients nonmalignant systemic disease ( cardiovascular , renal , hepatic , lung embolism , etc . ) would prevent prolonged followup . Patients treat systemic investigational drug within past 30 day . Breast cancer chemoprevention antiestrogens Hormone replacement therapy ( HRT ) stop least 4 week randomization Patients know HIV positive ( specific test require determine eligibility ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Postmenopausal breast cancer , radiohormonotherapy sequence</keyword>
	<keyword>ER+ and/or PgR+ ,</keyword>
	<keyword>Postmenopausal Breast cancer ,</keyword>
	<keyword>Adjuvant setting</keyword>
</DOC>